Literature DB >> 20929616

[Detection of Trypanosoma cruzi in blood donors].

Bárbara Alicia Novelo-Garza1, Gamaliel Benítez-Arvizu, América Peña-Benítez, Jorge Galván-Cervantes, Alejandro Morales-Rojas.   

Abstract

BACKGROUND: The American trypanosomiasis is the second parasitic disease in importance after paludism and one of the main mechanism of transmission is a blood transfusion. Our objective was to measure the effect the Tripanosoma Cruzi screening test in blood banks in the Mexican Institute of Social Security.
METHODS: Information was obtained from each unit of blood collected. The Tripanosoma cruzi prevalence was calculated only in samples with double reactivity in the blood banks.
RESULTS: Of 71 blood banks, only 26 had been doing T. Cruzi screen; after implementation of integrated services 55 are doing the screening. There were 935 donors with double reactivity to the T. Cruzi test from 230,074 samples. The national prevalence was 0.406%. The seroprevalence was 0.013% to 3.118%.
CONCLUSIONS: The screening of the T. cruzi improved the detection and increased the safety and the prevention of its transmission by blood transfusion.

Entities:  

Mesh:

Year:  2010        PMID: 20929616

Source DB:  PubMed          Journal:  Rev Med Inst Mex Seguro Soc        ISSN: 0443-5117


  7 in total

1.  Physician Knowledge, Attitudes, and Practices Related to Chagas Disease in Tabasco, Mexico.

Authors:  Brandon A Berger; Allison H Bartlett; Ricardo Jiménez-Hernández; Esmelin Trinidad Vázquez; Norma Galindo-Sevilla
Journal:  Am J Trop Med Hyg       Date:  2018-04-19       Impact factor: 2.345

2.  Atlas of Mexican Triatominae (Reduviidae: Hemiptera) and vector transmission of Chagas disease.

Authors:  Janine M Ramsey; A Townsend Peterson; Oscar Carmona-Castro; David A Moo-Llanes; Yoshinori Nakazawa; Morgan Butrick; Ezequiel Tun-Ku; Keynes de la Cruz-Félix; Carlos N Ibarra-Cerdeña
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-03-14       Impact factor: 2.743

3.  Including unpublished surveys in reviews on Chagas disease in Mexico.

Authors:  Pierre Buekens; Jorge López-Cárdenas; Eric Dumonteil; Nicolas Padilla-Raygoza
Journal:  Public Health Rev       Date:  2020-11-11

4.  Barriers to treatment access for Chagas disease in Mexico.

Authors:  Jennifer M Manne; Callae S Snively; Janine M Ramsey; Marco Ocampo Salgado; Till Bärnighausen; Michael R Reich
Journal:  PLoS Negl Trop Dis       Date:  2013-10-17

5.  Opportunity cost for early treatment of Chagas disease in Mexico.

Authors:  Janine M Ramsey; Miguel Elizondo-Cano; Gilberto Sanchez-González; Adriana Peña-Nieves; Alejandro Figueroa-Lara
Journal:  PLoS Negl Trop Dis       Date:  2014-04-17

6.  Seroprevalence of T. cruzi infection in blood donors and Chagas cardiomyopathy in patients from the coal mining region of Coahuila, Mexico.

Authors:  José Gerardo Martínez-Tovar; Eduardo A Rebollar-Téllez; Ildefonso Fernández Salas
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Mar-Apr       Impact factor: 1.846

7.  Cost-Effectiveness of Blood Donation Screening for Trypanosoma cruzi in Mexico.

Authors:  Gilberto Sánchez-González; Alejandro Figueroa-Lara; Miguel Elizondo-Cano; Leslie Wilson; Barbara Novelo-Garza; Leopoldo Valiente-Banuet; Janine M Ramsey
Journal:  PLoS Negl Trop Dis       Date:  2016-03-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.